Risperidone (oral forms) for people with schizophrenia

Turk, Tarek; Al‐Khatib, Mahmoud A.; Abbas, Ghadir; Jawish, Mhd Khaled; Alshar, Omar Mohammad Hammamieh; Alchamat, Hamza Abou; Essali, Adib

doi:10.1002/14651858.cd012822

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up until today (28 February 2020), this classification effort has detected new comparisons for review titles, new classes of drugs and new qualifiers from existing RCTs. These discoveries were assessed by Cochrane editors and led to start and, in some cases, accomplishment of at least 14 Cochrane reviews: six on qualifiers (Abbas et al, 2017; Hanafi et al, 2017; Latifeh et al, 2019; Turk, Alkhatib, et al, 2017; Turk, Zuhri Yafi, et al, 2017; Turkmani et al, 2019), one on a class of drugs (Karl et al, 2018) and nine on comparing two drugs (Bazrafshan et al, 2015; Chattopadhyay et al, 2016; Eslami Shahrbabaki et al, 2018; Ibragimov et al, 2019; Mazhari et al, 2017; Nikvarz et al, 2017; Nur & Adams, 2016; Schmidt et al, 2019; Zare & Bazrafshan, 2017).…”

Section: Discussionmentioning

confidence: 99%

Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis

Shokraneh

Adams

2021

Health Info Libraries J

View full text Add to dashboard Cite

Background Systematic reviewing is a time‐consuming and resource‐intensive process. Information specialists are maintaining study‐based registers to facilitate efficient conduct of systematic reviews. Classification of study‐level meta‐data ‐such as interventions –can result in much more accurate searches, saving time in the early steps of systematic reviewing. Objective To classify all pharmacological interventions from all schizophrenia trials. Methods We used Cochrane Schizophrenia's Study‐based Register as the source of trials, Emtree and MeSH for synonyms, AdisInsight and http://CT.gov for research drugs and WHO ATC for marketed drugs. Results One third of tested interventions on patients with schizophrenia are pharmacological (816; belonging to 106 clinical classes) with antipsychotic drugs being the most researched (15.1%). Only 528 of these medications are listed in WHO ATC. Around one third of these drug interventions are seen only in research (236; from 21 pharmacological/biochemical classes). Within the pharmacological interventions, we identified 28 ‘qualifiers’ including dose, route and timing of drug delivery. Conclusion Identification and classification of pharmacological interventions from trials require use of many sources of information none of which are inclusive of all drugs. Limitations of each source are helpful to understand. Classification of non‐pharmacological interventions is now a priority for clinical and information scientists and professionals.

show abstract